Free Trial

Evolus Q4 2023 Earnings Report

Evolus logo
$11.62 -0.11 (-0.94%)
(As of 10:27 AM ET)

Evolus Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Evolus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email.

About Evolus

Evolus (NASDAQ:EOLS), a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

View Evolus Profile

More Earnings Resources from MarketBeat

Upcoming Earnings